Lorenzo D'Ambrosio

Learn More
BACKGROUND Results of previous study showed promising but short-lived activity of sorafenib in the treatment of patients with unresectable advanced and metastatic osteosarcoma. This treatment failure has been attributed to the mTOR pathway and might therefore be overcome with the addition of mTOR inhibitors. We aimed to investigate the activity of sorafenib(More)
Unresectable metastatic bone sarcoma and soft-tissue sarcomas (STS) are incurable due to the inability to eradicate chemoresistant cancer stem-like cells (sCSC) that are likely responsible for relapses and drug resistance. In this study, we investigated the preclinical activity of patient-derived cytokine-induced killer (CIK) cells against autologous bone(More)
PURPOSE The multikinase inhibitor sorafenib displays antitumor activity in preclinical models of osteosarcoma. However, in sorafenib-treated patients with metastatic-relapsed osteosarcoma, disease stabilization and tumor shrinkage were short-lived and drug resistance occurred. We explored the sorafenib treatment escape mechanisms to overcome their(More)
The purpose of this paper is to study the approximation of vector valued mappings defined on a subset of a normed space. We investigate Korovkin-type conditions under which a given sequence of linear operators becomes a so-called approximation process. First, we give a sufficient condition for this sequence to approximate the class of bounded, uniformly(More)
n engl j med 371;14 nejm.org october 2, 2014 1362 tomography and are not aware that these two approaches have ever been compared adequately. Subjecting a patient to laparoscopy for “screen­ ing” before initiating treatment is a big step. Shapiro and colleagues allude to the use of treprostinil, a long­acting prostanoid, in Degos’s disease. We are aware of(More)
Allogeneic hematopoietic cell transplant (HCT) remains the only curative therapy for many hematologic malignancies but it is limited by high nonrelapse mortality (NRM), primarily from unpredictable control of graft-versus-host disease (GVHD). Recently, post-transplant cyclophosphamide demonstrated improved GVHD control in allogeneic bone marrow HCT. Here we(More)